Please login to the form below

Not currently logged in
Email:
Password:

Astellas posts positive bladder therapy data

Astellas has reported positive data from a phase III trial for its overactive bladder therapy candidate mirabegron

Astellas has reported positive data from a phase III trial for its overactive bladder therapy candidate mirabegron.

The data showed that 12 weeks of treatment with mirabegron once-daily led to significant improvements in the number of incontinence episodes, the frequency of urination per 24 hours, and patient-reported outcomes including disease perception, symptom interference and quality of life.

Mirabegron is a selective beta-3 adrenoceptor antagonist designed to facilitate filling of the bladder and storage of urine. A marketing authorisation application for the drug was submitted in Japan in June 2010.

Astellas expects to make regulatory filings in the US and Europe during the second half of 2011.

19th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics